XmAb®5574 (MOR208) is a humanized monoclonal antibody that targets the antigen CD19 for treatment of B cell malignancies, including chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL) and non-Hodgkin’s lymphoma (NHL). It contains a proprietary Xencor XmAb® Fc domain that enhances cytotoxic potency (ADCC) and also down regulates B cell activation. In June 2010, MorphoSys licensed worldwide rights to the compound, and is collaborating with Xencor on clinical development in oncology.
About CLL, ALL and NHL
It is estimated that there are approximately 77,000 new cases of NHL (66,000), CLL (8,000) and B-precursor ALL (3,000) diagnosed in the U.S. annually. While approximately 50% of patients with aggressive NHL may be cured by combination cytotoxic chemotherapy and immunotherapy, the majority of patients with indolent NHL and CLL will relapse and develop progressive disease. Consequently, identifying new therapies continues to be a priority for these diseases.